Table 5. Relationship between orbital exenteration and clinicopathologic and molecular factors.
| Univariate analysis | ||||
|---|---|---|---|---|
| Variables | N = 29 | HR | 95% CI | P |
| Age | Mean 77.3 years | 1.68 | 0.834–3.406 | 0.146 |
| Sex | Male 15, Female 14 | 0.925 | 0.129–6.605 | 0.938 |
| T-stage (AJCC) | Tis, T1, T2: 21/T3 ≥8 | 7.551 | 0.785–72.650 | 0.080 |
| EGFR staining | Focal 21/Diffuse 8 | 7.21 × 102 | 0.001–82.9 × 10 | 0.365 |
| EGFR membrane staining | Very strong 1/Strong 21/Weak 7/Negative 0 | 0.415 | 0.121–1.429 | 0.164 |
| EGFR cytoplasmic staining | Very strong 4/Strong 6/Weak 19/Negative 0 | 4.206 | 10.97–16.122 | 0.036* |
| EGFR mutation | Exon 19 E746-A750 del 8/Exon 21 L858R point mutation 2 | 0.582 | 0.096–3.545 | 0.558 |
| HPV positive | Positive 7/Negative 22 | 0.032 | 0.00–5.07 × 102 | 0.485 |
CI indicates confidence interval; HR hazard rate.
Statistically significant differences are underlined.
*p value based on the Cox proportional hazard model.